Iranian Journal of Microbiology 2016. 8(6):389-394.

Prevalence of Hepatitis C virus Genotype 3a in patients with Hodgkin and Non-Hodgkin Lymphoma
Hashem Radmehr, Manoochehr Makvandi, Alireza Samarbafzadeh, Ali Teimoori, Niloofar Neisi, Mojtaba Rasti, Sara Abasifar, Hasan Soltani, Samaneh Abbasi, Hadis Kiani, Hamide Mehravaran, Azarakhsh Azaran, Toran Shahani


Background and Objectives: Hepatitis C virus (HCV) is a major public health problem worldwide. Replication and persistence of HCV genome have been described in the liver tissue as well as B cells lymphocyte. Several investigations have reported that long-term persistence of HCV in B cells may result in Hodgkin and Non-Hodgkin lymphoma. This study was aimed to determine frequency of HCV RNA in histological tissues obtained from patients suffered from Hodgkin and Non-Hodgkin lymphoma.

Materials and Methods: 52 formalin-fixed paraffin-embedded tissue blocks including 23 (44.3%) Hodgkin and 29 (55.7%) Non-Hodgkin samples were collected and five micrometer sections were prepared. RNA was extracted and cDNA was synthesized. Two consecutive Nested RT-PCR assays were carried out for detection of HCV 5’ UTR and core gene. RT-PCR products were sequenced and aligned to construct HCV phylogenic tree to evaluate the homology of sequences in comparison to the reference sequences retrieved from Genbank.

Results: Overall, 6 Non-Hodgkin (20.6%) and 3 Hodgkin lymphoma (13.04%) samples showed positive PCR results for both 5’ UTR and HCV core RNA via nested PCR (P<0.469). Sequencing results revealed that all detected HCV RNA samples belonged to the genotype 3a.

Conclusion: Despite low prevalence of HCV infection in Iran, high frequency of HCV RNA genotypes 3a (17.3%) has been found in patients with Hodgkin and Non-Hodgkin lymphoma. To improve treatment regimens, screening of HCV RNA in patients suffered from Hodgkin or Non-Hodgkin lymphoma is recommended which can be done through highly sensitive molecular means before and after immunosuppression status.

Keywords: Nested RT-PCR, Hepatitis C virus, Hodgkin lymphoma, Non-Hodgkin lymphoma, Genotype


Nested. RT-PCR; Hepatitis C virus; Hodgkin lymphoma ; Non-Hodgkin lymphoma ;Genotype

Full Text:



Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; 61:S45-57.

Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45:529-538.

Halliday J, Klenerman P, Barnes E. Vaccination for hepatitis C virus: closing in on an evasive target. Ex- pert Rev Vaccines 2011; 10:659-672.

Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated cri- teria and genotype assignment web resource. Hepatol- ogy 2014; 59318-327.

Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV sero- prevalence. Hepatology 2013; 57:1333-1342.

Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an emerging infection. Arch Ira- nian Med 2005; 8: 84-90.

Machida K, McNamara G, Cheng KT, Huang J, Wang CH, Comai L, et al. Hepatitis C virus inhibits DNA damage repair through reactive oxygen and nitrogen species and by interfering with the ATM-NBS1/Mre11/ Rad50 DNA repair pathway in monocytes and hepato- cytes. J Immunol 2010; 185:6985-6998.

Deng L, Nagano-Fujii M, Tanaka M, Nomura-Takiga- wa Y, Ikeda M, Kato N, et al. NS3 protein of Hepatitis C virus associates with the tumour suppressor p53 and inhibits its function in an NS3 sequence-dependent manner. J Gen Virol 2006; 87:1703-1713

Canioni D, Michot JM, Rabiega P, Molina TJ, Charlotte F, Lazure T, et al. In Situ Hepatitis C NS3 protein de- tection is associated with high grade features in Hep- atitis C-Associated B-Cell Non-Hodgkin lymphomas. PLoS One 2016; 11:e0156384.

Peveling-Oberhag J, Arcaini L, Hansmann ML, Ze- uzem S. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol 2013; 59:169-177.

Armitage JO. Early-stage Hodgkin's lymphoma. N Engl J Med 2010; 363:653-662.

Gandhi MK, Tellam JT, Khanna R. Epstein-Barr vi- rus-associated Hodgkin's lymphoma. Br J Haematol 2004; 125:267-281.

Bagirath PV, Kumar JV, Arvind UD, Shailaja G. Ag- gressive extranodal peripheral T-cell non-Hodgkin's lymphoma: A rare case report and review. J Oral Max- illofac Pathol 2014; 18:80-83.

Morton LM. Dissecting lymphoma incidence to inform epidemiologic and clinical research. Leuk Lymphoma 2013; 54:1575-1576.

Yenice N, Gulluk F, Arican N, Turkmen S. HCV preva- lence in Hodg¬kin and non-Hodgkin lymphoma cases. Turk J Gasteroenterol 2003; 14:173-176.

Pozzato G, Mazzaro C, Crovatto M, Modolo ML, Ce- selli S, Mazzi G, et al. Low-grade malignant lympho- ma, hepatitis C virus infection, and mixed cryoglobu- linemia. Blood 1994; 84:3047-3053.

Economides MP, Mahale P, Turturro F, Hosry J, Sa- maniego F, Granwehr BP, et al. Development of non-Hodgkin lymphoma as a second primary cancer in hepatitis C virus-infected patients with a different pri- mary malignancy. Leuk Lymphoma 2017; 58:485-488.

Michot JM, Canioni D, Driss H, Alric L, Cacoub P, Suarez F, et al. Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lym- pho-C study. Am J Hematol 2015; 90:197-203.

Makvandi M, Khalaf khany D, Rasti M, Neisi N, Omid- varinia A, Mirghaed A, et al. Detection of Hepatitis C virus RNA in peripheral blood mononuclear cells of patients with abnormal alanine transaminase in Ahvaz. Indian J Med Microbiol 2014; 32:251-255.

Ohno O, Mizokami M, Wu RR, Saleh MG, Ohba K,Orito E, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol 1997; 35:201-207.

Keresztes K, Takács M, Horányi M, Miltényi Z, Illés Á. HCV and HGV Infection in Hodgkin’s Disease. Pathol Oncol Res 2003; 9:222-225.

Dal Maso L, Talamini R, Montella M, Crovatto M, Franceschi S. Hepatitis B and C viruses and Hodgkin lymphoma: a case-control study from Northern and Southern Italy. Haematologica 2004; 89:ELT17.

Iqbal T, Mahale P, Turturro F, Kyvernitakis A, Torres HA. Prevalence and association of hepatitis C virus in- fection with different types of lymphoma. Int J Cancer 2016;138:1035-1037.

Cowgill KD, Loffredo CA, Eissa SA, Mokhtar N, Ab- del-Hamid M, Fahmy A, et al. Case-control study of non-Hodgkin's lymphoma and hepatitis C virus infec- tion in Egypt. Int J Epidemiol 2004; 33:1034-1039.

Spinelli JJ, Lai AS, Krajden M, Andonov A, Gascoyne RD, Connors JM, et al. Hepatitis C virus and risk of non-Hodgkin lymphoma in British Columbia, Canada. Int J Cancer 2008; 122:630-633.

Mele A, Pulsoni A, Bianco E, Musto P, Szklo A, San- paolo MG, et al. Hepatitis C virus and B-cell non-Hod- gkin lymphomas: an Italian multicenter case-control study. Blood 2003; 102:996-999.

Khodabandehloo M, Roshani D. Prevalence of hepati- tis C virus genotypes in Iranian patients: a systematic review and meta-analysis. Hepat Mon 2014; 14:e22915.

Farshadpour F, Makvandi M, Samarbafzadeh AR, Jalalifar MA. Determination of hepatitis C virus gen- otypes among blood donors in Ahvaz, Iran. Indian J Med Microbiol 2010; 28:54-56.

Visco C, Finotto S. Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treat- ment. World J Gastroenterol 2014; 20:11054-11061.

Mazzaro C, De Re V, Spina M, Dal Maso L, Festini G, Comar C, et al. Pegylated-interferon plus ribavirin for HCV-positive indolent non-Hodgkin lymphomas. Br J Haematol 2009; 145:255-257.

Pellicelli AM, Zoli V. Role of ribavirin in hepatitis flare in HCV-infected patients with B cell non Hodgkin’s lymphoma treated with rituximab-containing regi- mens. Dig Liver Dis 2011;43:501-502.


  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.